| abstract |
FIELD: biotechnology.SUBSTANCE: invention relates to EGFRvIII-binding protein containing EGFRvIII-binding site, and its use. Disclosed is EGFRvIII-binding protein containing EGFRvIII-binding site, and, optionally, (i) containing at least one additional functional domain or (ii) being multispecific. EGFRvIII-binding site comprises an antibody heavy chain variable domain comprising CDR1 selected from the group consisting of SEQ ID No: 27, 33, 42, 46, 49, 53, YDFSSYWIG; CDR2, selected from a group, consisting of SEQ ID No: 28, 38, 43, 50, 54, 61, 63; and CDR3 with sequence SEQ ID No: 29, and an antibody variable light domain comprising CDR1 selected from a group consisting of SEQ ID No.: 30, 34, 36, 39, 44, 47, 51, 56, 59, 64; CDR2, selected from a group, consisting of SEQ ID No: 31, 40, 57, and CDR3, selected from a group consisting of SEQ ID No: 32, 35, 37, 41, 45, 48, 52, 55, 58, 60, 62 and 65. Also provided are a polynucleotide encoding said protein, an expression vector comprising said polynucleotide, a host cell for expressing EGFRvIII-binding protein, transformed or transfected with said vector, as well as a pharmaceutical composition for use in treating a tumour, comprising an effective amount of said EGFRvIII-binding protein, said vector or said host cell.EFFECT: invention enables to obtain highly specific EGFRvIII-binding protein with high affinity and provides specific and powerful destruction of solid cancerous tumours of several types.20 cl, 12 dwg, 7 tbl, 12 ex |